ArticleTargeted oncology2025

Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD.

Anna M Czarnecka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.